Effect of phlebotomy on lipid metabolism in subjects with hereditary hemochromatosis

Metabolism: Clinical and Experimental

Volumn 60, Issue 6, 2011, Pages 830-834

  Casanova Esteban, Paola ^a   Guiral, Nuria ^a   Andrés, Eva ^b   Gonzalvo, Carmen ^c   Mateo Gallego, Rocio ^a   Giraldo, Pilar ^a   Paramo, Jose A ^d   Civeira, Fernando ^a  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^d UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; TRANSFERRIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; FEMALE; FERRITIN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEMOCHROMATOSIS; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HYPERTRIGLYCERIDEMIA; IRON OVERLOAD; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; PHLEBOTOMY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TRANSFERRIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; BLOOD GLUCOSE; FEMALE; FERRITINS; GENOTYPE; HEMOCHROMATOSIS; HUMANS; IRON; IRON OVERLOAD; LIPID METABOLISM; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PHLEBOTOMY; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFERRIN; TRIGLYCERIDES; YOUNG ADULT;

EID: 79956103174     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2010.07.035     Document Type: Article

References (22)

1. Allen KJ, Gurrin LC, Constantine CC, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008;358:221-30.
2. Adams PC, Reboussin DM, Barton JC, et al. Hemochromatosis and Iron Overload Screening (HEIRS) Study Research Investigators. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005;352:1769-78.
3. Yen AW, Fancher TL, Bowlus CL. Revisiting hereditary hemochromatosis: current concepts and progress. Am J Med 2006;119:391-9.
4. Pietrangelo A. Hereditary hemochromatosis - a new look at an old disease. N Engl J Med 2004;350:2383-97.
5. Witte DL, Crosby Wh, Edwards CQ, et al. Practice guideline development task force of the College of American Pathologists: hereditary hemochromatosis. Clin Chim Acta 1996;245:13-200.
6. Mendler MH, Turlin B, Moirand R, et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999;117:1155-63. (Pubitemid 29512675)
7. Sun L, Franco OH, Hu FB, et al. Ferritin concentrations, metabolic syndrome, and type 2 diabetes in middle-aged and elderly Chinese. J Clin Endocrinol Metab 2008;93:4690-6.
8. Jehn ML, Guallar E, Clark JM, et al. A prospective study of plasma ferritin level and incident diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol 2007;165:1047-54. (Pubitemid 46598829)
9. Jehn M, Clark JM, Guallar E. Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care 2004;27:2422-8. (Pubitemid 39281396)
10. Equitani F, Fernandez-Real JM, Menichella G, et al. Bloodletting ameliorates insulin sensitivity and secretion in parallel to reducing liver iron in carriers of HFE gene mutations. Diabetes Care 2008;31:3-8.
11. Jiang R, Manson JE, Meigs JB, et al. Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA 2004;291:711-7. (Pubitemid 38543791)
12. Forouhi NG, Harding AH, Allison M, et al. Elevated serum ferritin levels predict new-onset type 2 diabetes: results from the EPIC-Norfolk prospective study. Diabetologia 2007;50:949-56. (Pubitemid 46559245)
13. Tuomainen TP, Nyyssonen K, Salonen R, et al. Body iron stores are associated with serum insulin and blood glucose concentrations. Population study in 1,013 eastern Finnish men. Diabetes Care 1997;20:426-8.
14. Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006;440:944-8.
15. Solanas-Barca M, Mateo-Gallego R, Calmarza P, et al. Mutations in HFE causing hemochromatosis are associated with primary hyper-triglyceridemia. J Clin Endocrinol Metab 2009;94:4391-7.
16. Mateo-Gallego R, Calmarza P, Jarauta E, et al. Serum ferritin is a major determinant of lipid phenotype in familial combined hyperlipidemia and familial hypertriglyceridemia. Metabolism 2010;59:154-8.
17. Valenti L, Fracanzani AL, Dongiovanni P, et al. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol 2007;102:1251-8. (Pubitemid 46802029)
18. Grundy SM, Cleeman JI, Daniels SR, et al. American Heart Association, National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005;112:2735-52. (Pubitemid 41532612)
19. Alegría E, Cordero A, Laclaustra M, et al. Prevalence of metabolic syndrome in the Spanish working population: MESYAS registry. Rev Esp Cardiol 2005;58:797-806. (Pubitemid 41131489)
20. Pankow JS, Boerwinkle E, Adams PC, et al. HFE C282Y homozygotes have reduced low-density lipoprotein cholesterol: the Atherosclerosis Risk in Communities (ARIC) Study. Transl Res 2008;152:3-10.
21. Forns X, Ampurdanès S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002;36:986-92.
22. Eriksson Moirand R, Mendler MH, Guillygomarc'h A, et al. Non-alcoholic steatohepatitis with iron: part of insulin resistance-associated hepatic iron overload? J Hepatol 2000;33:1024-6.